Study author, year | RT dose, Gy | Chemotherapy during RT | Adjuvant chemotherapy | Long-term outcomes |
STAR-01 Aschele C, 2016[1] | 50.4 | FU (225 mg/m2/day) +/– oxaliplatin (60 mg/m2 weekly) | FU-based adjuvant therapy was encouraged but not specified | No SS difference in OS |
ACCORD/PRODIGE1 Gerard JP, 2010, 2012[2,3] | 45 | Capecitabine (800 mg twice daily, 5 days/week) versus | Left to discretion of participating institutes + not reported | No SS difference in OS |
50 | Capecitabine (800 mg twice daily, 5 days/week) + oxaliplatin (50 mg/m2 weekly) | |||
PETACC-6 Schmoll HJ, 2018[4] | 45 (optional boost to 50.4) | Capecitabine (825 mg/m2 twice daily) versus | Capecitabine (1000 mg/m2 twice daily, days 1 to 15, every 21 days for 6 months) versus | No SS difference in DFS, OS, or locoregional control |
Capecitabine + oxaliplatin (50 mg/m2 weekly) | Same capecitabine dose + oxaliplatin (130 mg/m2 every 3 weeks for 6 months) | |||
CAO/ARO Rodel C, 2012, 2015[5,6] | 50.4 | FU infusion (1000 mg/m2/day, days 1 to 5 and 29 to 33) versus | Bolus FU (500 mg/m2 days 1 to 5 monthly for 4 months) versus | Three-year DFS 75.9 versus 71.2%, HR 0.79 (95% CI 0.64-0.98) |
FU infusion (250 mg/m2/day, days 1 to 14 and 22 to 35) + oxaliplatin (50 mg/m2 weekly) | FOLFOX (day 1 and 15 every 28 days for 4 months) | |||
NSABP R-04 Allegra CJ, 2015[7] | 50.4 | FU infusion (225 mg/m2/day) +/– oxaliplatin (50 mg/m2 weekly) or | FU-based adjuvant therapy was encouraged but not specified | No difference in OS, DFS, or locoregional control |
Capecitabine (825 mg/m2 twice daily) +/– oxaliplatin (50 mg/m2 weekly) |
Do you want to add Medilib to your home screen?